On March 6, 2026, the largest research peptide vendor in the United States posted a three-sentence shutdown notice and went dark. No raid, no indictment — just a calculated exit after months of mounting regulatory pressure and quality failures exposed by independent testing.
At approximately 2:00 PM Eastern on March 6, 2026, visitors to peptidesciences.com found a bare white page with a red-bordered notice: “After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products.”
No product catalog. No shopping cart. No explanation beyond “careful consideration.” A company that reportedly generated $7.4 million in online sales in December 2025 alone, according to e-commerce analytics firm Grips Intelligence, closed overnight.
The shutdown didn't come from nowhere. Three converging forces made continued operations untenable:
The SAFE Drugs Act prohibited selling research chemicals identical to FDA-approved drugs. Semaglutide, tirzepatide, and retatrutide — the highest-margin products — became legally untouchable overnight. For context, Hims & Hers earned $225 million from compounded semaglutide during the shortage period. The gray market segment was worth multiples of that.
The enforcement trajectory went from warning letters (late 2024) to a warehouse raid on Amino Asylum (June 2025) to criminal guilty pleas at Paradigm Peptides (December 2025). CDER warning letters jumped 50% in fiscal year 2025. Peptide Sciences already had a 2023 warning letter in their file.
Finnrick Analytics rated Peptide Sciences' retatrutide E (Bad) based on 34 independent samples. Quantities diverged up to 50% from advertised amounts. At least one sample was misidentified entirely — a compound labeled retatrutide was something else. For a brand built on "pharmaceutical-grade" credibility, this was fatal.
Domain peptidesciences.com registered. Henderson, NV virtual mailbox.
Proven Peptides shuts down. Peptide Sciences absorbs market share.
FDA warning letter for health claims about BPC-157 and TB-500.
FDA designates 17 peptides as Category 2 — banned from compounding.
Warning letters to Prime Peptides, SwissChems, Xcel Peptides, Summit Research.
Semaglutide shortage resolved. GLP-1 compounding window closes.
FDA raids Amino Asylum warehouse. Site goes permanently offline.
Finnrick Analytics rates Peptide Sciences retatrutide E (Bad) — 34 samples.
FDA issues 50+ warning letters to GLP-1 compounders. DOJ involvement confirmed.
SAFE Drugs Act prohibits research chemical sales of FDA-approved drug analogues.
RFK Jr. announces ~14 of 19 Category 2 peptides may return to Category 1.
Peptide Sciences posts shutdown notice. Operations cease immediately.
At least 10 major gray market peptide vendors have been shut down, raided, warned, or criminally prosecuted since late 2024.
| Vendor | Action | Date | Status |
|---|---|---|---|
| Peptide Sciences | Voluntary shutdown | Mar 2026 | Closed |
| Amino Asylum | FDA warehouse raid | Jun 2025 | Offline |
| Paradigm Peptides | Criminal guilty pleas | Dec 2025 | Convicted |
| Tailor Made Compounding | Guilty plea, $1.79M forfeiture | 2025 | Convicted |
| SwissChems | FDA warning letter + ITC complaint | Dec 2024 | Warning |
| Prime Peptides | FDA warning letter | Dec 2024 | Warning |
| Xcel Peptides | FDA warning letter | Dec 2024 | Warning |
| Summit Research | FDA warning letter | Dec 2024 | Warning |
| Pinnacle Peptides | FDA warning letter | Dec 2025 | Warning |
| Science.bio | Ceased operations | Jan 2026 | Closed |
The gray market's biggest and most trusted name just closed. The remaining options fall into two buckets: established vendors likely next on the FDA's list, and newer operations with unknown quality controls filling the vacuum.
The Category 2 ban already eliminated compounding pharmacy access to BPC-157, TB-500, CJC-1295, Ipamorelin, and 13 other popular peptides. GLP-1 research chemicals are legislated off the market. The walls are closing in.
The RFK Jr. wildcard: On February 27, 2026, RFK Jr. announced that approximately 14 of 19 Category 2 peptides may return to Category 1, making them available through licensed compounding pharmacies again. If implemented, this would re-legalize BPC-157, Thymosin Alpha-1, AOD-9604, Semax, Selank, KPV, and MOTS-c for compounding with a prescription. No formal FDA action has been published yet.
Look for vendors with recent Finnrick or equivalent lab results. Not self-reported COAs — independent samples submitted by customers.
If a vendor only accepts crypto and peer-to-peer apps, that's a red flag. Legitimate operations maintain bank-grade payment processing.
Check if the vendor has received FDA warning letters. Our supplier profiles track this.
One clean batch means nothing. Look for vendors with testing history spanning months, not a single data point.
A virtual mailbox is not a lab. Verify the vendor has legitimate operations, not just a website.
We maintain quality scores on 16 suppliers with trust ratings of 65+. See who's still operating, compare pricing, and check independent testing status.
This article is based on publicly available data, third-party analytics, independent testing results, and verified social media posts. Peptide Markets is an independent comparison directory. We do not sell peptides or provide medical advice. Always consult a qualified healthcare provider before beginning any peptide therapy. For research and educational purposes only.